186 reports of this reaction
3.7% of all AMPICILLIN SODIUM AND SULBACTAM SODIUM reports
#2 most reported adverse reaction
PNEUMONIA is the #2 most commonly reported adverse reaction for AMPICILLIN SODIUM AND SULBACTAM SODIUM, manufactured by Roerig. There are 186 FDA adverse event reports linking AMPICILLIN SODIUM AND SULBACTAM SODIUM to PNEUMONIA. This represents approximately 3.7% of all 4,969 adverse event reports for this drug.
Patients taking AMPICILLIN SODIUM AND SULBACTAM SODIUM who experience pneumonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PNEUMONIA is moderately reported among AMPICILLIN SODIUM AND SULBACTAM SODIUM users, representing a notable but not dominant share of adverse events.
In addition to pneumonia, the following adverse reactions have been reported for AMPICILLIN SODIUM AND SULBACTAM SODIUM:
The following drugs have also been linked to pneumonia in FDA adverse event reports:
PNEUMONIA has been reported as an adverse event in 186 FDA reports for AMPICILLIN SODIUM AND SULBACTAM SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
PNEUMONIA accounts for approximately 3.7% of all adverse event reports for AMPICILLIN SODIUM AND SULBACTAM SODIUM, making it one of the most commonly reported side effect.
If you experience pneumonia while taking AMPICILLIN SODIUM AND SULBACTAM SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.